Conference Proceedings

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts

D Rischin, M Gil-Martin, A Gonzalez-Martin, I Brana, JY Hou, D Cho, G Falchook, S Formenti, S Jabbour, K Moore, A Naing, KP Papadopoulos, J Baranda, A Weise, MG Fury, M Feng, J Li, I Lowy, M Mathias

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2018

Grants

Funding Acknowledgements

Regeneron Pharmaceutical Inc. and Sanofi.